Annual report
4539.TEDINET S100R0RK
Period2022-04-01 → 2023-03-31
Filed2023-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥31.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥32.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥31.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥34.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥241m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥825m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥58m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥582m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥307m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥480m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥976m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥339m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥700m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥495m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥436m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥881m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥339m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥700m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥48.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥47.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥45.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥46.9bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥30.0bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥31.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥17.4bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥17.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥9.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥916m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥394m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥35m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥326m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥960m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥144m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥793m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥29m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥961m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥110m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥94.07 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.33 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.42 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥245.11 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,130.65 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,119.99 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,006.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,830.92 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,963.24 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 38.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 872 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 809 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 760 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 807 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 846 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥24.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥24.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥25.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥355m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥983m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥2m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥690m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥309m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥574m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥560m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥113m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥349m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥249m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥643m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥86m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥479m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥35.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥35.1bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥34.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥32.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥34.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.7bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥24.1bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥10.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.1bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥10.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥11.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥8.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-95.59 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.32 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥176.96 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.77 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.89 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥50 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,802.53 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,004.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,034.03 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,867.4 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,081.9 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.7% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -3.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,261,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 349 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 347 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 352 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 403 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 450 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥34m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥60m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 67 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥64m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥31m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥31m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥9.6bn |
| Medicinereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥540m |
| Medicinereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Medicinereportable segment | employees | at 2023-03-31 | 768 pure |
| Medicinereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥30.6bn |
| Medicinereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥30.5bn |
| Medicinereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥9m |
| Medicinereportable segment | segment assets | at 2023-03-31 | ¥37.1bn |
| Medicinereportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥306m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥574m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥39.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | −¥241m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥26m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥62m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥96m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥42m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥8.9bn |
| Medicinereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Medicinereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥31.5bn |
| Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥31.5bn |
| Medicinereportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10m |
| Medicinereportable segment | segment assets | at 2022-03-31 | ¥38.6bn |
| Medicinereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥729m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥32.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥32.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥40.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥825m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 1 pure |
| Medicinereportable segment | employees | at 2023-03-31 | 311 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,674
| Item | Context | Value | Unit |
|---|---|---|---|
| Loss on valuation of investment securities | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Loss on valuation of investment securities | Prior1YearDuration_ReconcilingItemsMember | 10000000 | JPY |
| Loss on valuation of investment securities | Prior1YearDuration | 10000000 | JPY |
| Loss on valuation of inventories el | Prior1YearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 162000000 | JPY |
| Loss on valuation of inventories el | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Loss on valuation of inventories el | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 162000000 | JPY |
| Loss on valuation of inventories el | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Loss on valuation of inventories el | Prior1YearDuration | 162000000 | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 124000000 | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 124000000 | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration | 124000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 1105000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 26000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 1131000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration | 1131000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 30543000000 | JPY |
| Revenues from external customers | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1015000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 31559000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 31559000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 9000000 | JPY |
| Transactions with other segments | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 22000000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 31000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -31000000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 30552000000 | JPY |
| Net sales | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1038000000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 31590000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -31000000 | JPY |
| Net sales | CurrentYearDuration | 31559000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | -306000000 | JPY |
| Operating income | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 64000000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | -241000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYearDuration | -241000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 37120000000 | JPY |
| Assets | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1833000000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 38954000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 9617000000 | JPY |
| Assets | CurrentYearInstant | 48571000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | 1439000000 | JPY |
| Depreciation segment information | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 60000000 | JPY |
| Depreciation segment information | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1500000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Depreciation segment information | CurrentYearDuration | 1500000000 | JPY |
| Extraordinary income | CurrentYearDuration_jpcrp030000-asr_E00957-000MedicineReportableSegmentsMember | － | JPY |
| Extraordinary income | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 10000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |